middle.news
How Telix’s Illuccix Phase 3 Win Could Transform Prostate Cancer Imaging in China
8:40am on Monday 22nd of December, 2025 AEDT
•
Healthcare
Read Story
How Telix’s Illuccix Phase 3 Win Could Transform Prostate Cancer Imaging in China
8:40am on Monday 22nd of December, 2025 AEDT
Key Points
Illuccix Phase 3 study in China meets primary endpoint with 94.8% positive predictive value
67.2% of patients had treatment plans altered based on Illuccix imaging results
Telix finalizing NDA resubmission for TLX101-CDx (Pixclara) following FDA collaboration
FDA alignment reached on remediation plans for TLX250-CDx (Zircaix) manufacturing issues
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Telix Pharmaceuticals (ASX:TLX)
OPEN ARTICLE